TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04072562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7594
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.
Study: NCT01200862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug company code: BGS649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug company code: BGS649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00619138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual cognitive-behavioural therapy
Description: 1 session per week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stepped care model
Description: three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
Study: NCT03997968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851
Description: Part A and B: Daily oral doses of CYT-0851 for 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851
Description: Part A and B: Daily oral doses of CYT-0851 for 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851
Description: Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
Study: NCT01141764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Scan
Description: The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Testing
Description: On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on.
Study: NCT02695771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Cancer chemotherapeutic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Cancer chemotherapeutic agent
Study: NCT01500135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TachoSil®
Description: TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel® Original
Description: Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
Study: NCT04559932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracheostomy Training Course
Description: A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
Study: NCT02018666

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAVA endotracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA endotracheal tube
Study: NCT03997968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851 in combination with gemcitabine
Description: Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851 in combination with capecitabine
Description: Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851 in combination with rituximab and bendamustine
Description: Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
Study: NCT02514603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV
Study: NCT03775031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Laser and Chemical Peel
Description: Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
Study: NCT04187703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: 5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
Study: NCT03985046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Chemotherapy
Description: Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
Study: NCT03775031

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional Laser and Chemical Peel
Description: Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
Study: NCT02043301

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bococizumab (PF-04950615; RN316)
Description: Single 150 mg PF-04950615 dose administered SC to the abdomen
Study: NCT02725060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
Study: NCT02925143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning course in neuromuscular monitoring
Description: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
Study: NCT02725060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoproterenol
Description: Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
Study: NCT04018729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zephyr Endobronchial Valve
Description: Endoscopic lung volume reduction therapy.
Study: NCT02725060

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 25 micro-Ci of radiation
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture study with blood samples
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-hour heart rhythm and blood pressure monitoring
Description: Blood pressure, heart rate and ECG monitoring for 24 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Axonal Sudomotor Reflex Testing
Description: The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
Study: NCT03775031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Laser and Chemical Peel
Description: Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Laser and Chemical Peel
Description: Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
Study: NCT02725060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autonomic function tests
Description: The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebreathing test
Description: Cardiac output will be measured using the rebreathing technique (Innocor)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of splanchnic capacitance
Description: Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microneurography
Description: microneurography will be measured in the peroneal nerve to assess sympathetic activity.
Study: NCT02171897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Study: NCT01406249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP
Description: Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP
Description: Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
Study: NCT04559750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered behavior therapy (I-BT)
Description: 10 weeks of I-BT
Study: NCT01086930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReJoyce Workstation
Description: The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
Study: NCT04018729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zephyr Endobronchial Valve
Description: Endoscopic lung volume reduction therapy.
Study: NCT02576197

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
Study: NCT04520230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid
Description: inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg capsule inhaled once daily + Budesonide
Description: inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Tiotropium
Description: long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
Study: NCT01198691

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insorb absorbable staples
Description: Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insorb
Description: Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
Study: NCT04367389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Description: Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
Study: NCT03129997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten test food
Description: Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten test food
Description: Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
Study: NCT03295942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-336B11
Description: OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
Study: NCT04018729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marrow-derived mesenchymal stromal cell
Description: Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
Study: NCT00903045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride
Description: Propiverine hydrochloride 20mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo twice a day
Study: NCT02695888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risky Driving Prevention
Description: The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Healthy Living
Description: The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
Study: NCT02254460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test
Description: Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
Study: NCT04764019

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution intestinal manometry
Description: Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
Study: NCT02043301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: Single 150 mg PF-04950615 dose administered SC to the upper arm
Study: NCT04462185

Intervention type: DIAGNOSTIC_TEST
Intervention: A genomic and transcriptomic landscape analysis
Description: A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.
Study: NCT01642407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
Study: NCT01558193

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance
Study: NCT02043301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: Single 150 mg PF-04950615 dose administered SC to the thigh
Study: NCT04529551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1601A
Description: A filtered, king size cigarette with a menthol capsule in the filter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1601A
Description: A filtered, king size cigarette with a menthol capsule in the filter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1601B
Description: A filtered, king size cigarette with a menthol capsule in the filter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1601B
Description: A filtered, king size cigarette with a menthol capsule in the filter.
Study: NCT03851276

Intervention type: RADIATION
Group type: OTHER
Intervention: Multi-sliced computed tomography (MSCT)
Description: Surgery planning done based solely on MSCT.
Study: NCT01133210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: dosage will be a 300mg Maraviroc pill twice a day for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
Study: NCT01558193

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-vitamin/mineral
Description: Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
Study: NCT06142305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DDH surgery and casting
Description: DDH surgery and casting
Study: NCT02093520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MILD Procedure
Description: The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Injection of epidural steroids into the lumbar spine
Study: NCT04369612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard post-transplant follow-up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based monitoring
Description: Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
Study: NCT01558193

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid
Description: 22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA plus vitamins/minerals
Description: The DHA and vitamin/mineral supplements are as above